Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria

January 08, 2019

Researchers from LSTM have looked at the efficacy of using a novel artemisinin-based combination therapy (ACT), pyronaridine-artesunate, to treat malaria in areas where resistance to other ACTs is becoming a problem. The analysis finds it at least as effective as the currently used ACTs, if not better.

The World Health Organization (WHO) recommends ACTs to treat uncomplicated Plasmodium falciparum (P. falciparum) malaria. However, concerns over rising artemisinin resistance have led global initiatives to develop new partner drugs to protect their efficacy.

In this update of a Cochrane Review, independent LSTM authors Joseph Pryce and Paul Hine assessed the efficacy of pyronaridine-artesunate in treating malaria. They found that the treatment was as good, if not better than other ACTs; and while some people receiving it have liver function tests suggesting mild liver injuries, there was no evidence that this injury was severe or irreversible.

LSTM's Dr Hine is corresponding author on the review. He said: "The need to find novel ACTs is important so that we can protect the efficacy of the artemisinin derivatives within them. The evidence that we found clearly showed at pyronaridine-artesunate performs as well, if not better than some of the currently marketed ACTs."

The review team looked at the results from 10 included trials that compared pyronaridine-artesunate with other currently-used treatments for P. falciparum malaria. Five of the studies looked specifically at the safety of the drug, and two of the trials exclusively recruited children under the age of 12.

Joe Pryce, one of the authors, said: "We found that pyronaridine-artesunate did increase the risk of having blood tests that showed mild liver injury, but there was no evidence that this caused severe or irreversible damage. The findings of this review's efficacy analysis support the recommendation for using pyronaridine-artesunate in areas of multiple drug resistance, providing effective malaria treatment where other treatments may be failing."
-end-
This Cochrane Review was co-ordinated by the Cochrane Infectious Diseases Group (CIDG), which has its editorial base at LSTM. The CIDG has been in operation since 1994 and consists of over 600 authors from 52 countries and is supported by UK aid from the UK Government for the benefit of low- and middle-income countries (project number 300342-104).

Liverpool School of Tropical Medicine

Related Malaria Articles from Brightsurf:

Clocking in with malaria parasites
Discovery of a malaria parasite's internal clock could lead to new treatment strategies.

Breakthrough in malaria research
An international scientific consortium led by the cell biologists Volker Heussler from the University of Bern and Oliver Billker from the UmeƄ University in Sweden has for the first time systematically investigated the genome of the malaria parasite Plasmodium throughout its life cycle in a large-scale experiment.

Scientists close in on malaria vaccine
Scientists have taken another big step forward towards developing a vaccine that's effective against the most severe forms of malaria.

New tool in fight against malaria
Modifying a class of molecules originally developed to treat the skin disease psoriasis could lead to a new malaria drug that is effective against malaria parasites resistant to currently available drugs.

Malaria expert warns of need for malaria drug to treat severe cases in US
The US each year sees more than 1,500 cases of malaria, and currently there is limited access to an intravenously administered (IV) drug needed for the more serious cases.

Monkey malaria breakthrough offers cure for relapsing malaria
A breakthrough in monkey malaria research by two University of Otago scientists could help scientists diagnose and treat a relapsing form of human malaria.

Getting to zero malaria cases in zanzibar
New research led by the Johns Hopkins Center for Communication Programs, Ifakara Health Institute and the Zanzibar Malaria Elimination Program suggests that a better understanding of human behavior at night -- when malaria mosquitoes are biting -- could be key to preventing lingering cases.

Widely used malaria treatment to prevent malaria in pregnant women
A global team of researchers, led by a research team at the Liverpool School of Tropical Medicine (LSTM), are calling for a review of drug-based strategies used to prevent malaria infections in pregnant women, in areas where there is widespread resistance to existing antimalarial medicines.

Protection against Malaria: A matter of balance
A balanced production of pro and anti-inflammatory cytokines at two years of age protects against clinical malaria in early childhood, according to a study led by ISGlobal, an institution supported by ''la Caixa'' Foundation.

The math of malaria
A new mathematical model for malaria shows how competition between parasite strains within a human host reduces the odds of drug resistance developing in a high-transmission setting.

Read More: Malaria News and Malaria Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.